
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Clinical Cancer Research, Vol 1, Issue 10 1103-1110, Copyright © 1995 by American Association for Cancer Research
ARTICLES |
FA Sinicrope, J Hart, F Michelassi and JJ Lee
Departments of Gastrointestinal Medical Oncology and Digestive Diseases and Biomathematics, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
The bcl-2 proto-oncogene encodes a Mr 25,000 protein that has been shown to prevent apoptosis or programmed cell death. The bcl-2 protein is detectable in basal cells of normal colonic epithelium, and an altered topographic distribution of this protein is found in colonic neoplasms. However, the clinical significance of abnormal bcl-2 expression in colon carcinomas remains unknown. We examined the prognostic value of the bcl-2 protein in TNM stage II colon carcinomas and its relationship to DNA ploidy, cell proliferation indices, p53 expression, and clinicopathological features. We analyzed 119 resected and otherwise untreated, paraffin-embedded stage II colon carcinomas for bcl-2 and p53 protein expression using immunohistochemistry. DNA ploidy and proliferative index (% S-phase + % G2-M) were determined by flow cytometry, and tumor grade and vascular microinvasion were assessed on histological sections. Cytoplasmic expression of the bcl-2 protein was detected in 72 (66%) of 110 carcinomas, and a high level of expression was significantly correlated with diploid DNA content (P = 0.02) and low proliferative activity (P = 0.005). bcl-2 was not associated with nuclear p53 expression. In a univariate analysis, a higher fraction of bcl-2-positive tumor cells was associated with better relapse-free survival (P = 0.02) and overall survival (P = 0.05) rates. Moreover, a high level of bcl-2 expression was an independent predictor of better relapse-free survival (P = 0.04), but not overall survival (P = 0.14), after adjustment for other variables, including proliferative index, DNA ploidy, and race. In conclusion, bcl-2 overexpression is associated with favorable prognostic features and may predict clinical outcome in stage II colon carcinomas.
This article has been cited by other articles:
![]() |
A. R. Shoemaker, A. Oleksijew, J. Bauch, B. A. Belli, T. Borre, M. Bruncko, T. Deckwirth, D. J. Frost, K. Jarvis, M. K. Joseph, et al. A Small-Molecule Inhibitor of Bcl-XL Potentiates the Activity of Cytotoxic Drugs In vitro and In vivo. Cancer Res., September 1, 2006; 66(17): 8731 - 8739. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Lyall, S. R. Dundas, S. Curran, and G. I. Murray Profiling Markers of Prognosis in Colorectal Cancer Clin. Cancer Res., February 15, 2006; 12(4): 1184 - 1191. [Abstract] [Full Text] [PDF] |
||||
![]() |
E Cristi, G Perrone, G Toscano, A Verzi, S Nori, D Santini, G Tonini, A Vetrani, A Fabiano, and C Rabitti Tumour proliferation, angiogenesis, and ploidy status in human colon cancer J. Clin. Pathol., November 1, 2005; 58(11): 1170 - 1174. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Lin, R. Lai, L. R. Chirieac, C. Li, V. A. Thomazy, I. Grammatikakis, G. Z. Rassidakis, W. Zhang, Y. Fujio, K. Kunisada, et al. Constitutive Activation of JAK3/STAT3 in Colon Carcinoma Tumors and Cell Lines: Inhibition of JAK3/STAT3 Signaling Induces Apoptosis and Cell Cycle Arrest of Colon Carcinoma Cells Am. J. Pathol., October 1, 2005; 167(4): 969 - 980. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Krajewska, H. Kim, C. Kim, H. Kang, K. Welsh, S.-i. Matsuzawa, M. Tsukamoto, R. G. Thomas, N. Assa-Munt, Z. Piao, et al. Analysis of Apoptosis Protein Expression in Early-Stage Colorectal Cancer Suggests Opportunities for New Prognostic Biomarkers Clin. Cancer Res., August 1, 2005; 11(15): 5451 - 5461. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. M. Boman, R. Walters, J. Z. Fields, A. J. Kovatich, T. Zhang, G. A. Isenberg, S. D. Goldstein, and J. P. Palazzo Colonic Crypt Changes during Adenoma Development in Familial Adenomatous Polyposis: Immunohistochemical Evidence for Expansion of the Crypt Base Cell Population Am. J. Pathol., November 1, 2004; 165(5): 1489 - 1498. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. L. Hayward, J. S. Macpherson, J. Cummings, B. P. Monia, J. F. Smyth, and D. I. Jodrell Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent: Genetic evidence for specificity of the antisense effect Mol. Cancer Ther., February 1, 2004; 3(2): 169 - 178. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. L. Hayward, J. S. Macpherson, J. Cummings, B. P. Monia, J. F. Smyth, and D. I. Jodrell Antisense Bcl-xl Down-Regulation Switches the Response to Topoisomerase I Inhibition from Senescence to Apoptosis in Colorectal Cancer Cells, Enhancing Global Cytotoxicity Clin. Cancer Res., July 1, 2003; 9(7): 2856 - 2865. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. H. Pierce, M. E. Vail, L. Ralph, J. S. Campbell, and N. Fausto Bcl-2 Expression Inhibits Liver Carcinogenesis and Delays the Development of Proliferating Foci Am. J. Pathol., May 1, 2002; 160(5): 1555 - 1560. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. H. Meterissian, M. Kontogiannea, M. Al-Sowaidi, A. Linjawi, F. Halwani, B. Jamison, and M. Edwardes Bcl-2 Is a Useful Prognostic Marker in Dukes' B Colon Cancer Ann. Surg. Oncol., July 1, 2001; 8(6): 533 - 537. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Srivastava, M. Verma, and D. E. Henson Biomarkers for Early Detection of Colon Cancer Clin. Cancer Res., May 1, 2001; 7(5): 1118 - 1126. [Abstract] [Full Text] |
||||
![]() |
A. Biroccio, B. Benassi, I. D'Agnano, C. D'Angelo, S. Buglioni, M. Mottolese, A. Ricciotti, G. Citro, M. Cosimelli, R. G. Ramsay, et al. c-Myb and Bcl-x Overexpression Predicts Poor Prognosis in Colorectal Cancer : Clinical and Experimental Findings Am. J. Pathol., April 1, 2001; 158(4): 1289 - 1299. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Konopleva, A. M. Tari, Z. Estrov, D. Harris, Z. Xie, S. Zhao, G. Lopez-Berestein, and M. Andreeff Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins Blood, June 15, 2000; 95(12): 3929 - 3938. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. A. Sinicrope, J. Hart, H.-A. Hsu, M. Lemoine, F. Michelassi, and L. C. Stephens Apoptotic and Mitotic Indices Predict Survival Rates in Lymph Node-negative Colon Carcinomas Clin. Cancer Res., July 1, 1999; 5(7): 1793 - 1804. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. Hogarth and A. G. Hall Increased BAX Expression Is Associated With an Increased Risk of Relapse in Childhood Acute Lymphocytic Leukemia Blood, April 15, 1999; 93(8): 2671 - 2678. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |